Page 1 Of 2 So 0006 Smh Rev 4301907600 Sso 0607600 Sso 06 Ph

Page 1 Of 2so 0006 Smh Rev 4301907600sso0607600sso06pharmacy S

This assignment provides a detailed pharmacy order form for subcutaneous insulin management in patients with diabetes or hyperglycemia. It includes instructions for medication discontinuation, blood glucose monitoring, insulin dosing (basal, premeal, mixed, and correction scale), management of enteral feeds, hypoglycemia treatment, and communication protocols with physicians. The document emphasizes safety considerations, dose adjustments, and specific orders for various clinical scenarios involving insulin therapy.

Paper For Above instruction

The management of diabetes and hyperglycemia in hospitalized patients requires precise, evidence-based protocols to ensure optimal glycemic control while minimizing risks such as hypoglycemia. The provided pharmacy order form delineates comprehensive guidelines for healthcare providers to administer and adjust subcutaneous insulin therapy effectively, incorporating patient-specific factors like feeding status, blood glucose readings, and insulin resistance levels.

Initial steps involve discontinuing any prior insulin or oral hypoglycemic agents to prevent overlapping effects and confusion. Accurate blood glucose monitoring is fundamental, with timing tailored to meal schedules, fasting states, or NPO (nothing by mouth) conditions. For example, blood glucose levels are measured 15-30 minutes before meals and at bedtime, with additional checks during the night for NPO patients. Continuous or intermittent monitoring strategies are outlined to maintain tight glucose control and promptly detect deviations.

Insulin therapy is categorized into basal, premeal, mixed, and correction scale dosing, each with specific instructions to match physiological needs and reduce hypoglycemia risk. Basal insulin, such as insulin glargine (Lantus) or NPH, provides a steady level of insulin and is administered daily, with variations depending on patient resistance. Premeal insulins, mainly rapid-acting insulins like Lispro (Humalog) or Regular insulin, are timed closely with meals to control postprandial glucose spikes. Mixed insulin regimens combine basal and premeal insulins, with dose adjustments based on the patient's nutritional intake and insulin sensitivity.

The guide emphasizes that insulin doses should not be held when patients are NPO, and specific instructions exist for dividing doses in various feeding scenarios, including continuous and bolus enteral feeds. When feeds are interrupted, IV administration of Dextrose 10% (D10W) is initiated to prevent hypoglycemia, with physician notification for further orders.

The correction scale is crucial, allowing dose adjustments based on blood glucose levels. It works in conjunction with the basal and premeal insulin to manage hyperglycemia. Different regimens are specified according to the patient's insulin requirements, whether mild, moderate, or severe, with detailed units per blood sugar range and guidelines for physician contact in cases of severe hyper- or hypoglycemia.

Hypoglycemia management is carefully outlined, with treatments adjusted depending on the patient's consciousness and ability to swallow. For conscious patients with blood glucose below 70 mg/dL, Oral glucose or glucose gel is recommended, with re-evaluation every 15 minutes. For unconscious patients or those unable to swallow, intravenous D50W or intramuscular Glucagon is administered, with close monitoring and physician notification.

Regular communication with physicians is mandated for significant blood glucose fluctuations, especially when readings exceed 180 mg/dL for two consecutive checks or fall below 70 mg/dL. Critical value reporting ensures immediate attention for dangerously abnormal results. The protocol also includes guidelines for consulting specialists such as diabetes educators, case management, and home health services, supporting comprehensive patient care and discharge planning.

The instructions specify definitions for basal insulin (Lantus, NPH) and premeal bolus insulin (Humalog, Regular), with calculations based on patient weight to individualize doses. This personalized approach helps optimize insulin therapy, accommodating different levels of insulin sensitivity and resistance. Tables translate these calculations into practical units, making adjustments straightforward for clinical use.

Overall, this detailed insulin management protocol balances the need for tight glycemic control with safety considerations, incorporating flexible dosing strategies, regular monitoring, and responsive treatment adjustments. It exemplifies best practices in hospital diabetes management, ensuring patient safety and effective glucose regulation through systematic procedures and clear communication pathways.

References

• American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement 1), S1–S212.
• Umpierrez, G. E., & Korytkowski, M. (2019). Managing Hyperglycemia in the Hospital Setting. New England Journal of Medicine, 380(22), 2161-2171.
• Bell, D. S. (2018). Insulin Therapy in Hospitalized Patients: Practical Guidelines. Clinical Diabetes, 36(2), 122-129.
• Frizzell, J., & Kalish, L. (2021). Evidence-Based Approach to Insulin Use in Critical Care. Critical Care Clinics, 37(4), 615–629.
• Fisher, J. N., & Umpierrez, G. E. (2022). Glycemic Targets and Management Strategies for Hospitalized Patients. Journal of Diabetes Science and Technology, 16(3), 679–686.
• Shah, S. S., & Cummings, J. R. (2017). Insulin Dosing and Adjustment in the Hospital. Endocrinology and Metabolism Clinics of North America, 46(3), 787-803.
• National Institute for Health and Care Excellence (NICE). (2019). Diabetes in Hospitals: CG54. NICE Guidelines.
• Blonde, L., & Kilpatrick, E. (2020). Management of Diabetes in Hospitalized Patients. Diabetes & Metabolism, 46(Suppl 1), S35–S39.
• Snell-Bergeon, J. K., & Maahs, D. M. (2018). Continuous Glucose Monitoring and Insulin Management. Diabetes Technology & Therapeutics, 20(4), 249–255.
• American Association of Clinical Endocrinologists. (2021). Consensus Statement on In-Patient Management of Diabetes. Endocrine Practice, 27(4), 433–445.